Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Group 1 - Precision BioSciences reported a quarterly loss of $2.21 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of -413.95% [1] - The company posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 99.71%, compared to revenues of $17.58 million a year ago [2] - The stock has increased approximately 29.9% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] Group 2 - The earnings outlook for Precision BioSciences is currently unfavorable, with a Zacks Rank of 4 (Sell), indicating expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $13.7 million, and -$1.17 on revenues of $45.6 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry is ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]